ASMB ASSEMBLY BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1426800 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY80.2%
TTM net income YoY71.2%
TTM EPS YoY116.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-31.8%
Net margin-16.6%
FCF margin-60.7%
EBITDA margin-31.7%
Returns
ROE-4.6%
ROA-3.9%
ROIC (approx.)-7.8%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets8.1%
Debt / equity0.00x
Current ratio12.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.65x
Accruals ratio10.4%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $72.30M | $28.52M |
| R&D expense | $64.81M | $55.93M |
| SG&A expense | $19.61M | $18.01M |
| Operating income | -$12.12M | -$45.42M |
| Pretax income | -$6.12M | -$39.85M |
| Income tax | $0 | $330,000 |
| Net income | -$6.12M | -$40.18M |
| EBITDA | -$11.99M | -$45.29M |
| EPS (basic) | -0.55 | -6.69 |
| EPS (diluted) | -0.55 | -6.69 |
| Weighted avg. shares (diluted) | 11.21M | 6.00M |
| Balance sheet | ||
| Cash & equivalents | $58.45M | $38.34M |
| Short-term investments | $189.66M | $73.73M |
| Receivables | $974,000 | $0 |
| Current assets | $254.55M | $115.50M |
| PP&E, net | $221,000 | $284,000 |
| Total assets | $257.59M | $119.17M |
| Current liabilities | $48.78M | $47.80M |
| Total liabilities | $50.84M | $85.81M |
| Shareholders' equity | $206.75M | $33.36M |
| Shares outstanding | 15.86M | 7.46M |
| Cash flow statement | ||
| Operating cash flow | -$41.09M | -$51.12M |
| Capital expenditure | $66,000 | $28,000 |
| Free cash flow | -$41.16M | -$51.15M |
| Investing cash flow | -$113.47M | $40.17M |
| Financing cash flow | $174.67M | $29.45M |
| Depreciation & amortization | $129,000 | $129,000 |
| Stock-based compensation | $4.68M | $3.12M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.